GB0417367D0 - Pharmaceutical composition containing botulinum neurotoxin - Google Patents

Pharmaceutical composition containing botulinum neurotoxin

Info

Publication number
GB0417367D0
GB0417367D0 GBGB0417367.0A GB0417367A GB0417367D0 GB 0417367 D0 GB0417367 D0 GB 0417367D0 GB 0417367 A GB0417367 A GB 0417367A GB 0417367 D0 GB0417367 D0 GB 0417367D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0417367.0A
Other versions
GB2416692A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Ltd
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Priority to GB0417367A priority Critical patent/GB2416692A/en
Publication of GB0417367D0 publication Critical patent/GB0417367D0/en
Priority to ES05767871.6T priority patent/ES2526912T3/en
Priority to ES05767945.8T priority patent/ES2526913T3/en
Priority to PT141808758T priority patent/PT2813239T/en
Priority to US11/659,448 priority patent/US20080069841A1/en
Priority to EP14180875.8A priority patent/EP2813239B1/en
Priority to EP05767945.8A priority patent/EP1778279B1/en
Priority to HUE14180875A priority patent/HUE032950T2/en
Priority to PT57678716T priority patent/PT1776137E/en
Priority to PCT/GB2005/003036 priority patent/WO2006013357A1/en
Priority to EP05767871.6A priority patent/EP1776137B1/en
Priority to US11/659,449 priority patent/US20080102090A1/en
Priority to DK14180875.8T priority patent/DK2813239T3/en
Priority to TR2017/08749T priority patent/TR201708749T4/en
Priority to PCT/GB2005/003057 priority patent/WO2006013370A1/en
Priority to PL14180875T priority patent/PL2813239T3/en
Priority to ES14180875.8T priority patent/ES2627627T3/en
Priority to PL05767871T priority patent/PL1776137T3/en
Priority to DK05767871.6T priority patent/DK1776137T3/en
Priority to EP17161071.0A priority patent/EP3210620A1/en
Publication of GB2416692A publication Critical patent/GB2416692A/en
Priority to US12/748,733 priority patent/US20100184689A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A61K2201/06—
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0417367A 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin Withdrawn GB2416692A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GB0417367A GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin
EP17161071.0A EP3210620A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP05767871.6A EP1776137B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
DK14180875.8T DK2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PT141808758T PT2813239T (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
US11/659,448 US20080069841A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2
EP14180875.8A EP2813239B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
EP05767945.8A EP1778279B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
HUE14180875A HUE032950T2 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PT57678716T PT1776137E (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PCT/GB2005/003036 WO2006013357A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
ES05767871.6T ES2526912T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
US11/659,449 US20080102090A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
ES05767945.8T ES2526913T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin 2
TR2017/08749T TR201708749T4 (en) 2004-08-04 2005-08-03 PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM NEUROTOXIN A2
PCT/GB2005/003057 WO2006013370A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PL14180875T PL2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
ES14180875.8T ES2627627T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PL05767871T PL1776137T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
DK05767871.6T DK1776137T3 (en) 2004-08-04 2005-08-03 A pharmaceutical composition comprising botulinum neurotoxin A2
US12/748,733 US20100184689A1 (en) 2004-08-04 2010-03-29 Pharmaceutical Composition Containing Botulinum Neurotoxin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0417367A GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin

Publications (2)

Publication Number Publication Date
GB0417367D0 true GB0417367D0 (en) 2004-09-08
GB2416692A GB2416692A (en) 2006-02-08

Family

ID=32982513

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0417367A Withdrawn GB2416692A (en) 2004-08-04 2004-08-04 Pharmaceutical composition containing botulinum neurotoxin

Country Status (1)

Country Link
GB (1) GB2416692A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043009A1 (en) 2004-09-06 2006-03-23 Toxogen Gmbh Transport protein for introducing chemical compounds into nerve cells
DE102005019302A1 (en) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier for targeting nerve cells
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
FR2902341B1 (en) 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
FR2907680B1 (en) 2006-10-27 2012-12-28 Scras THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN INDUCED BY AT LEAST ONE ANTI-CANCER AGENT
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS.
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY
MX358613B (en) * 2012-03-12 2018-08-27 J Binder William Treatment of migraine headaches with presynaptic neurotoxin.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
EP1053014A4 (en) * 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol

Also Published As

Publication number Publication date
GB2416692A (en) 2006-02-08

Similar Documents

Publication Publication Date Title
IL180380A0 (en) Pharmaceutical composition containing botulinum neurotoxin
PL1776137T3 (en) Pharmaceutical composition containing botulinum neurotoxin a2
IL225848A0 (en) Therapeutic composition with a botulinum neurotoxin
IL177480A0 (en) Pharmaceutical composition
ZA200606154B (en) Pharmaceutical composition comprising pimobendan
EP1871347A4 (en) Pharmaceutical composition
EP1937255A4 (en) Pharmaceutical composition
EP1862184A4 (en) Pharmaceutical composition
EP1889613A4 (en) Pharmaceutical composition comprising vitamin k
HU0401177D0 (en) Pharmaceutical composition
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB2411355B (en) Pharmaceutical composition
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200701931B (en) Pharmaceutical composition
HUP0500813A2 (en) Pharmaceutical composition containing violaceae extract
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin
HK1216998A1 (en) Pharmaceutical compositions comprising botulinum neurotoxin
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)